Quince Therapeutics Considers Strategic Alternatives; Shares Up 11% to $14.25

Quince Therapeutics (NASDAQ: QNCE) is exploring strategic alternatives following a review of its business, according to a regulatory filing dated February 10, 2026. The company's shares surged 11% to $14.25 in after-hours trading, reflecting heightened speculation about potential mergers, acquisitions, or a sale. The filing noted the board is evaluating options to realize the value of its pipeline, including the potential development of a new cancer immunotherapy treatment. QNCE reported revenue of $28.5 million in fiscal 2024, with a net loss of $42.1 million, reflecting ongoing R&D investments. The stock has gained 42% year-to-date, outpacing the broader biotech sector.